News | April 24, 2025
Laurus Labs Q4 FY25 PAT up 208% to Rs. 234 Cr
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
Before joining Sun Pharma, Tulla served as Senior Vice President and Chief Commercial Head – Acute Cluster at Cipla
Subscribe To Our Newsletter & Stay Updated
